Comparison of helicobacter pylori eradication rate with four different quadruple regimens in dyspeptic patients.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013010612024N1

Enrollment

270

Registered

2013-02-13

Start date

2009-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection with Helicobacter pylori. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Group“A”: who received omeprazole 20mg / BID+amoxicillin1g/BID +bismuth subcitrate240 mg/ BID +clarithromycin 500mg / BID for 2 weeks (73 patients). Intervention 2: Group B: Treatmen

Treatment - Drugs

Group“A”: who received omeprazole 20mg / BID+amoxicillin1g/BID +bismuth subcitrate240 mg/ BID +clarithromycin 500mg / BID for 2 weeks (73 patients)

Group B: Treatment with omeprazole 20mg / BID + tetracycline 500 mg/ QID+ bismuth subcitrate 240 mg/BID + metronidazole 250 mg/ QID for two weeks (46 patients)

Group C: Treatment with omeprazole 20mg / BID + amoxicillin1g/ BID + furazolidone 200mg/BID + bismuth subcitrate 240 mg/ BID for two weeks (64 patients)

Group D: The first week : omeprazole 20mg / BID + amoxycillin 1g/ BID + bismuth subcitrate 240mg/BID + Furazolidone200 mg/ BID then the second week: omeprazole 20mg / BID + amoxicillin 1g/ BID + bis

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with positive rapid urea’s test that confirmed with histological finding of helicobacter pylori infection and chronic gastritis were entered in study. Persons under 18 years of age at the time of endoscopy; those in the last month or bismuth compounds contain any antibiotics for any illness received; Pregnant and lactating women; people with serious diseases such as congestive heart failure; end-stage renal failure; cirrhosis and psychosis; patients with active gastrointestinal bleeding (upper); previous use of H. pylori eradication regimen and any favism patients were excluded from the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Eradication of Helicobacter pylori. Timepoint: 6 weeks after end of treatment. Method of measurement: UBT.	—

Secondary

Measure	Time frame
Side effects of treatment. Timepoint: At the time of treatment. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNaghashi Shahnaz

Liver and gastrointestinal diseases research center of Tabriz University of Medical Sciences

naghashish@tbzmed.ac.ir+98 41 1336 7473

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026